T1	Participants 275 330	acute antimigraine efficacy comparable to oral triptans
T2	Participants 364 427	migraine patients who cannot be adequately helped with triptans
T3	Participants 755 762	N = 660
T4	Participants 819 826	N = 248
T5	Participants 881 888	N = 407
